Genfit SA logo

Genfit SANASDAQ: GNFT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

27 March 2019

Next earnings report:

04 April 2025

Last dividends:

N/A

Next dividends:

N/A
$224.58 M
-31%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector
-90%vs. 3y high
62%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 15 Nov 2024 14:30:00 GMT
$4.50-$0.04(-0.77%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

GNFT Latest News

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
globenewswire.com13 November 2024 Sentiment: POSITIVE

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 13, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today provided a corporate update ahead of The Liver Meeting 2024®2.

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
globenewswire.com09 July 2024 Sentiment: POSITIVE

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
globenewswire.com17 June 2024 Sentiment: POSITIVE

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH1 in the European Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

US FDA approves Genfit and Ipsen's liver disease drug
reuters.com10 June 2024 Sentiment: POSITIVE

The U.S. Food and Drug Administration has approved French drugmakers Ipsen and Genfit's drug to treat a chronic inflammatory liver disease, Ipsen said on Monday.

GENFIT: May 22, 2024 Combined Shareholders Meeting Results
globenewswire.com22 May 2024 Sentiment: POSITIVE

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 22, 2024. The quorum on first convening amounted to 27.25% and shareholders approved all of the resolutions.

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
GlobeNewsWire02 November 2023 Sentiment: POSITIVE

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present an update on its scientific and corporate progress at The Liver Meeting® 2023 organized by the American Association for the Study of Liver Diseases (AASLD), which will take place in Boston, MA (USA) from November 10-14, 2023.

GENFIT to Participate in Upcoming Investor Conferences
GlobeNewsWire05 September 2023 Sentiment: POSITIVE

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) , September 05 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investor conferences.

Genfit shares fall despite positive trial results for rare cholestatic liver disease therapeutic
Proactive Investors30 June 2023 Sentiment: POSITIVE

GENFIT (NASDAQ:GNFT) shares fell 5% after initially rising on positive results from its clinical trial with partner Ipsen for the investigational therapeutic elafibranor in patients with the rare cholestatic liver disease primary biliary cholangitis (PBC).   The two companies announced on Friday that the Phase 3 ELATIVE trial met its primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to the placebo.

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease
Market Watch30 June 2023 Sentiment: POSITIVE

The U.S.-listed stock of Genfit S.A. GNFT, -5.48% GNFT, +22.56% soared 27% premarket Friday, after the French biotech and partner Ipsen IPSEY, +7.22% IPN, +0.27% announced positive results from a late-stage trial of a treatment for a rare liver disease.

What type of business is Genfit SA?

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

What sector is Genfit SA in?

Genfit SA is in the Healthcare sector

What industry is Genfit SA in?

Genfit SA is in the Biotechnology industry

What country is Genfit SA from?

Genfit SA is headquartered in France

When did Genfit SA go public?

Genfit SA initial public offering (IPO) was on 27 March 2019

What is Genfit SA website?

https://www.genfit.com

Is Genfit SA in the S&P 500?

No, Genfit SA is not included in the S&P 500 index

Is Genfit SA in the NASDAQ 100?

No, Genfit SA is not included in the NASDAQ 100 index

Is Genfit SA in the Dow Jones?

No, Genfit SA is not included in the Dow Jones index

When was Genfit SA the previous earnings report?

No data

When does Genfit SA earnings report?

The next expected earnings date for Genfit SA is 04 April 2025